Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (161-170 of 205) with videos related to

Pageof 21
Sort By:
Plos Biology|March 26, 2013
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survivalDaniel Thomas, Jason A Powell, Benjamin D Green, et al.
Leukemia|November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remissionIlaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Blood|December 2, 2006
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus, Hagop M Kantarjian, Michele Baccarani, et al.
Haematologica|August 10, 2012
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapySabrina Angelini, Simona Soverini, Gloria Ravegnini, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Nature Communications|January 28, 2018
A dual role for the N-terminal domain of the IL-3 receptor in cell signallingSophie E Broughton, Timothy R Hercus, Tracy L Nero, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Nature Communications|November 9, 2021
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemiaNadia El Khawanky, Amy Hughes, Wenbo Yu, et al.
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Pageof 21

Showing results (161-170 of 205) with videos related to

Sort By:
Pageof 21
Plos Biology|March 26, 2013
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survivalDaniel Thomas, Jason A Powell, Benjamin D Green, et al.
Leukemia|November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remissionIlaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Blood|December 2, 2006
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus, Hagop M Kantarjian, Michele Baccarani, et al.
Haematologica|August 10, 2012
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapySabrina Angelini, Simona Soverini, Gloria Ravegnini, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Nature Communications|January 28, 2018
A dual role for the N-terminal domain of the IL-3 receptor in cell signallingSophie E Broughton, Timothy R Hercus, Tracy L Nero, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Nature Communications|November 9, 2021
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemiaNadia El Khawanky, Amy Hughes, Wenbo Yu, et al.
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Pageof 21